Anticholinergic effects represent a multifaceted spectrum of physiological and psychological manifestations precipitated by the competitive inhibition of acetylcholine at central and peripheral cholinergic receptors. These actions, whether elicited as intentional therapeutic outcomes or unintended adverse events, wield a transformative influence over neural signaling, autonomic regulation, and cognitive homeostasis across diverse patient populations.
Anticholinergic Effects
1. Concise Definition
Anticholinergic effects are physiological and psychological sequelae resulting from the competitive or non-competitive antagonism of the neurotransmitter acetylcholine across muscarinic or nicotinic receptors. In clinical pharmacology, the term primarily denotes the unintended adverse reactions and pharmacodynamic outcomes that occur when therapeutic compounds impede parasympathetic nerve impulses and central cholinergic pathways.
These effects manifest along a broad continuum, spanning mild peripheral perturbations—such as xerostomia, anhidrosis, pupillary dilation, and constipation—to profound central nervous system disruptions, including delirium, memory fragmentation, and visual hallucinations. Because acetylcholine serves as a principal regulator of the autonomic nervous system and neurocognitive functioning, the blockade of cholinergic transmission impacts almost every physiological organ system.
In psychiatric, geriatric, and internal medicine, the evaluation of anticholinergic effects is of paramount diagnostic and prognostic significance. A thorough appreciation of these effects requires delineating the fine boundary between target therapeutic actions, such as smooth muscle relaxation or the mitigation of extrapyramidal symptoms, and adverse off-target pharmacological burdens that elevate morbidity and long-term neurocognitive decline.
2. Etymology & Linguistic Origin
The term anticholinergic is derived from a synthesis of classical Greek linguistic roots and nineteenth-century chemical nomenclature. The prefix anti- originates from the Ancient Greek ἀντί (antí), signifying “against,” “in opposition to,” or “counteractive.” The intermediary morpheme cholin- traces to the Greek χολή (cholē), meaning “bile,” which was historically applied in 1862 by German chemist Adolph Strecker upon his isolation of choline from porcine bile. The suffix -ergic originates from the Greek ἔργον (érgon), translated as “work,” “action,” or “activity.”
Consequently, the word etymologically describes any agent that acts in direct opposition to the physiological work executed by choline and its bioactive ester derivative, acetylcholine. The term was formally incorporated into biomedical discourse in the early to mid-twentieth century as neuropharmacologists sought standardized terminology to distinguish agents that antagonize postganglionic parasympathetic nerve terminals from sympathomimetic or adrenergic compounds.
3. Pronunciation & Grammatical Form
The term is pronounced phonetically as /ˌæn.ti.koʊ.ləˈnɜːr.dʒɪk ɪˈfɛkts/ in General American English, and as /ˌæn.tiˌkɒl.ɪˈnɜː.dʒɪk ɪˈfɛkts/ in Received Pronunciation British English.
Grammatically, anticholinergic functions both as an adjective and as a substantive noun. When modifying a noun—as in “anticholinergic effects,” “anticholinergic syndrome,” or “anticholinergic toxicity”—it denotes the property of opposing acetylcholine-mediated signaling. In its plural nominal form, “anticholinergics,” it designates a comprehensive pharmacological class of therapeutic substances and botanical alkaloids possessing these inhibitory characteristics. The accompanying term “effects” functions as a plural countable noun derived from the Latin effectus, designating the downstream results, operations, or phenomena provoked by an operative agent.
4. Detailed Conceptual Explanation
To conceptualize anticholinergic effects, one must examine the fundamental organization of the cholinergic system. Acetylcholine functions as an omnipresent signaling molecule within the human body. In the peripheral nervous system, it mediates communication at somatic neuromuscular junctions and across preganglionic autonomic fibers, as well as postganglionic parasympathetic neuroeffector junctions. Within the central nervous system, cholinergic pathways project extensively from nuclei in the basal forebrain—such as the nucleus basalis of Meynert—and the pedunculopontine tegmental nucleus, innervating the cerebral cortex, hippocampus, and striatum to coordinate attention, information encoding, executive control, and sensory processing.
Cholinergic receptors are classified into two primary superfamilies: ionotropic nicotinic acetylcholine receptors (nAChRs), which operate as ligand-gated ion channels, and metabotropic muscarinic acetylcholine receptors (mAChRs), which operate via G-protein-coupled signaling cascades. While both receptor types can be blocked, classical anticholinergic effects observed in standard clinical practice almost universally refer to the pharmacological antagonism of muscarinic receptors (subtypes M1 through M5). When an exogenous antagonist occupies these binding pockets without inducing receptor activation, it prevents endogenous acetylcholine from executing its typical cellular cascade, arresting parasympathetic signaling and dampening central cholinergic tone.
The physical manifestation of this antagonism follows an organ-specific trajectory dictated by receptor distribution. In peripheral tissues, muscarinic antagonism impedes smooth muscle contraction, diminishes exocrine gland secretion, accelerates sinoatrial node automaticity, and halts ciliary muscle accommodation. Consequently, patients exhibit pronounced reduction in lacrimation, salivation, and perspiration. Concurrently, the inhibition of bladder detrusor contractility promotes urinary retention, while decelerated gastrointestinal transit precipitates severe peristaltic delay.
Centrally, the attenuation of acetylcholine signaling disorganizes synaptic plasticity and thalamocortical gating. Acetylcholine regulates signal-to-noise ratios in cortical processing; depriving the cerebral mantle of cholinergic input results in fragmented consciousness, impaired working memory, spatial disorientation, and neurobehavioral agitation. The balance between central and peripheral penetration is heavily dictated by the molecular weight, lipophilicity, and tertiary versus quaternary amine architecture of the offending pharmaceutical compound.
5. Historical Development
The documentation of anticholinergic phenomena dates back to antiquity, long preceding the molecular characterization of neurotransmitters. Ancient civilizations throughout the Mediterranean, Asia, and the Americas recognized the physiological and intoxicating sequelae provoked by plants of the Solanaceae nightshade family, including Atropa belladonna, Hyoscyamus niger (henbane), and Datura stramonium. Ingestion of these botanical specimens induced the classical symptoms of cycloplegia, fever, dry mouth, hyperactive delirium, and hallucinations. During the Renaissance, Italian women administered drops distilled from Atropa belladonna into their eyes to induce mydriasis for aesthetic purposes, giving the plant its name (“beautiful lady”).
The nineteenth century marked the transition from empirical toxicology to chemical isolation. In 1831, the German pharmacist Heinrich F. G. Mein isolated the alkaloid atropine in crystalline form. Shortly thereafter, scopolamine (hyoscine) was extracted from henbane, permitting the first controlled experimental investigations of parasympathetic suppression. During early twentieth-century physiological research, Sir Henry Dale and Otto Loewi systematically elucidated chemical neurotransmission, demonstrating that Loewi’s “Vagusstoff” was indeed acetylcholine, and demonstrating that atropine selectively suppressed its postganglionic actions.
Mid-twentieth-century medicine witnessed an explosion in synthetic pharmacology, during which anticholinergic properties were intentionally synthesized or inadvertently acquired across novel drug classes. The advent of first-generation antihistamines (e.g., diphenhydramine) in the 1940s, followed by phenothiazine antipsychotics (e.g., chlorpromazine) and tricyclic antidepressants (e.g., amitriptyline) in the 1950s, revealed that many psychoactive medications were potent muscarinic antagonists. By the late twentieth and early twenty-first centuries, epidemiological research spearheaded by geriatricians and clinical pharmacologists shifted attention from acute intoxication toward the insidious hazards of chronic low-level anticholinergic burden, linking cumulative exposure directly to reversible delirium, structural neurodegeneration, and increased incidence of dementia.
6. Theoretical Foundations
The physiological and toxicological understanding of anticholinergic effects rests upon classical pharmacological receptor theory, particularly competitive receptor antagonism and occupancy dynamics. According to the mass-action occupancy model, the degree of anticholinergic response correlates with the concentration of the antagonist at the receptor site relative to endogenous acetylcholine concentrations and the intrinsic dissociation constant ($K_d$) of the drug-receptor complex.
Complementary to direct receptor kinetics is the cholinergic deficit hypothesis of cognitive aging and neurodegeneration. This neurobiological framework posits that the preservation of human cognitive function—specifically sustained attention, episodic memory encoding, and executive processing—is fundamentally reliant upon intact, robust cholinergic innervation radiating from the basal forebrain to the neocortex. Anticholinergic substances artificially induce an acute, functional state of cholinergic hypofunction that mimics and accelerates the neurochemical architecture of Alzheimer’s disease, providing empirical verification that central muscarinic neurotransmission is essential for structural cognitive stability.
Furthermore, autonomic balance theory explains the systemic sequelae of anticholinergic pharmacology. The autonomic nervous system operates through dynamic, homeostatic antagonism between its sympathetic and parasympathetic divisions. Under standard physiological conditions, constant parasympathetic tone maintains cardiac deceleration, enhances digestive enzyme output, and mediates micturition. When muscarinic receptors are occupied by an antagonist, parasympathetic tone is suppressed, unmasking unopposed sympathetic hyperactivity. Thus, manifestations such as sinus tachycardia, diaphoresis inhibition, and pupillary dilation represent both direct blockade of parasympathetic actions and the unrestrained predominance of sympathetic motor output.
7. Key Components, Types & Dimensions
Anticholinergic effects are conceptually stratified along two principal axes: the anatomical site of manifestation (peripheral versus central) and the specific muscarinic receptor subtype targeted by the pharmacological compound.
- Peripheral Anticholinergic Effects: These effects stem from the blockade of muscarinic receptors located on peripheral autonomic effector organs. Primary manifestations include:
- Ocular: Blockade of M3 receptors on the pupillary sphincter muscle precipitates passive mydriasis (photophobia), while inhibition of the ciliary muscle causes cycloplegia (loss of near-vision accommodation).
- Glandular / Secretory: Antagonism of M3 receptors on salivary, lacrimal, and bronchial glands induces xerostomia (dry mouth), xerophthalmia (dry eyes), and inspissated respiratory secretions. Blockade of cutaneous eccrine glands leads to anhidrosis, impeding heat dissipation and predisposing individuals to hyperpyrexia.
- Cardiovascular: Antagonism of M2 receptors located within the sinoatrial and atrioventricular nodes eliminates vagal inhibitory input, yielding sinus tachycardia and shortened atrioventricular nodal conduction times.
- Gastrointestinal: Disruption of M2 and M3 signaling along the enteric nervous system decelerates smooth muscle peristalsis, resulting in delayed gastric emptying, severe constipation, and potentially paralytic ileus.
- Urological: Blockade of M2 and M3 receptors within the bladder detrusor muscle decreases tone and contractile amplitude while increasing trigone and sphincter tone, resulting in hesitancy, dysuria, and acute urinary retention.
- Central Anticholinergic Effects: These effects arise when lipophilic molecules cross the blood-brain barrier to interrupt signaling across cortical and subcortical regions. Primary manifestations include:
- Cognitive Impairment: Decreased processing speed, immediate recall deficits, working memory erosion, and executive dysfunction driven primarily by M1 receptor antagonism within the neocortex and hippocampus.
- Neuropsychiatric Alterations: Acute confusional states, delirium, visual and auditory hallucinations, agitation, restlessness, and paranoia.
- Sleep Architecture Disruption: Suppression of rapid eye movement (REM) sleep and general sleep fragmentation due to the attenuation of cholinergic activity in the mesopontine tegmentum.
- Muscarinic Receptor Subtypes:
- M1 Receptors: Predominantly situated within the cerebral cortex, hippocampus, and peripheral sympathetic ganglia; mediates cognitive processing, synaptic plasticity, and gastric acid secretion.
- M2 Receptors: Located centrally and within cardiac tissue (atria, sinoatrial and AV nodes); modulates cardiac pacing, central negative feedback autoregulation, and smooth muscle tone.
- M3 Receptors: Highly concentrated across exocrine glands, visceral smooth muscle (bronchial, vascular, detrusor, intestinal), and vascular endothelium; orchestrates secretion, bronchoconstriction, and micturition.
- M4 and M5 Receptors: Expressed within striatal pathways, substantia nigra, and ventral tegmental areas; implicated in dopamine modulation, behavioral reinforcement, motor coordination, and vascular compliance.
8. Examples & Illustrative Cases
The manifestation of anticholinergic effects is encountered across multiple clinical specialties. The following real-world scenarios illustrate how these pharmacological dynamics operate in practical medical environments.
Case Illustration 1: Polypharmacy-Induced Delirium in an Older Adult
An 78-year-old female with a medical history of hypertension, mild osteoarthritis, and overactive bladder presented to an emergency department with progressive confusion, visual hallucinations, and acute functional deterioration over four days. Her family noted that she had become disoriented to time and place, saw unfamiliar people standing in her hallway, and had not experienced a bowel movement in over 72 hours. Upon physical examination, the patient was restless, with dry oral mucosa, warm and flushed skin, a pulse of 108 beats per minute, dilated pupils that were sluggishly reactive to light, and suprapubic fullness. An automated bladder scan revealed 650 milliliters of retained urine.
Review of her pharmacological regimen identified that she had been maintained on oxybutynin (an antispasmodic for overactive bladder) for six months. Three weeks prior, her primary care physician had initiated amitriptyline at bedtime for neuropathic joint discomfort. Additionally, the patient had been taking over-the-counter diphenhydramine nightly for emergent insomnia. The synergistic convergence of these three distinct anticholinergic agents led to an acute anticholinergic toxidrome characterized by concurrent central delirium, severe peripheral hyposecretion, urinary retention, and gastrointestinal stasis. Following catheter decompression, cessation of the culprit medications, and intravenous hydration, her sensorium cleared fully over forty-eight hours.
Case Illustration 2: Intentional Therapeutic Use in Movement Disorders
A 42-year-old male with treatment-resistant schizophrenia managed with haloperidol developed profound extrapyramidal symptoms, specifically resting tremor, cogwheel rigidity, and akathisia, attributed to robust dopamine D2-receptor blockade in the striatum. To counteract this extrapyramidal syndrome, the treating psychiatrist co-prescribed benztropine, a centrally active anticholinergic agent. By competitively blocking M1 receptors within striatal interneurons, benztropine restored the relative neurochemical equilibrium between dopamine and acetylcholine, resolving the rigidity and tremor. However, the patient subsequently reported chronic xerostomia and blurred vision during close-range reading, demonstrating the narrow therapeutic window between targeted extrapyramidal mitigation and peripheral adverse sequelae.
9. Measurement & Assessment
Quantifying anticholinergic effects involves physical clinical assessment, standardized toxicological heuristics, and validated quantitative scoring tools designed to estimate cumulative pharmacological exposure.
Clinically, acute severe anticholinergic toxicity is evaluated through classic diagnostic mnemonics that encapsulate peripheral and central autonomic signs:
- “Blind as a bat” (mydriasis and paralysis of accommodation)
- “Mad as a hatter” (delirium, cognitive fragmentation, and hallucinations)
- “Red as a beet” (cutaneous vasodilation to compensate for the loss of sweating)
- “Hot as a hare” (hyperthermia stemming from anhidrosis)
- “Dry as a bone” (cessation of salivary, lacrimal, and diaphoresis secretions)
- “Bowel and bladder lose their tone” (urinary retention and paralytic ileus)
In chronic outpatient, psychiatric, and geriatric settings, clinicians use predictive validated instruments termed Anticholinergic Burden Scales. These scales assign an ordinal risk score (typically ranging from 0 for no activity to 3 for severe activity) to individual pharmaceutical compounds based on in vitro receptor affinity assays and clinical consensus panels. When aggregated across an individual’s total prescription and non-prescription regimen, the resulting sum provides an objective index of potential adverse exposure.
Widely utilized risk measurement scales include the Anticholinergic Cognitive Burden (ACB) Scale, developed by Boustani and colleagues; the Anticholinergic Risk Scale (ARS), formulated by Rudolph et al.; and the Drug Burden Index (DBI), which integrates both anticholinergic and sedative exposures using a dose-dependent mathematical model. Patients exhibiting an aggregate ACB score equal to or exceeding 3 points are at significantly elevated risk for cognitive decline, falls, functional dependence, and premature mortality.
10. Applications & Practical Significance
Understanding anticholinergic effects is foundational to clinical decision-making, patient safety protocols, and rational pharmacology. Anticholinergic properties are leveraged for intentional clinical therapeutics across diverse medical specialties:
- Anesthesiology & Critical Care: Glycopyrrolate and atropine are administered preoperatively or intraoperatively to blunt excessive vagal reflexes, sustain heart rate during surgical manipulation, and dry copious tracheobronchial and salivary secretions.
- Pulmonary Medicine: Inhaled quaternary anticholinergic agents—such as ipratropium and tiotropium—block M3 receptors on bronchial smooth muscle, functioning as potent bronchodilators in the management of chronic obstructive pulmonary disease (COPD) and acute asthma exacerbations.
- Ophthalmology: Topical muscarinic antagonists, including tropicamide and cyclopentolate, are systematically applied to induce diagnostic mydriasis and cycloplegia for funduscopic evaluations and post-surgical uveitis management.
- Urology: Muscarinic antagonists like solifenacin, tolterodine, and darifenacin serve as standard pharmacotherapies to suppress involuntary detrusor contractions in patients with urge incontinence and overactive bladder.
- Gastroenterology: Agents such as hyoscyamine and dicyclomine alleviate painful smooth muscle spasm associated with irritable bowel syndrome.
Conversely, recognizing unintentional anticholinergic effects is critical for reducing adverse drug reactions. In geriatric psychiatry and family medicine, the phenomenon of the “prescribing cascade” frequently occurs when an unrecognized anticholinergic side effect is misinterpreted as a novel medical condition. For example, a patient receiving a tricyclic antidepressant who develops urinary hesitancy may be erroneously prescribed an alpha-blocker, or an individual experiencing diphenhydramine-induced memory loss may be prematurely diagnosed with early-stage dementia. Systematically identifying anticholinergic effects averts such diagnostic errors and unnecessary pharmacological interventions.
11. Research & Empirical Evidence
Over the past three decades, extensive epidemiological and neuroimaging literature has linked chronic anticholinergic exposure to structural and functional neurodegenerative processes. Large-scale longitudinal cohort studies have reshaped clinical guidelines regarding the long-term safety profile of these agents.
A landmark population-based nested case-control study conducted by Coupland et al. (2019), which analyzed over 284,000 individuals, established a significant dose-dependent association between the long-term prescription of anticholinergic drugs—specifically antidepressants, antiparkinsonian agents, bladder antimuscarinics, and antipsychotics—and an elevated risk of incident dementia up to two decades after initial exposure. Patients with the highest exposure category demonstrated nearly a 50% relative increase in the odds of developing dementia compared to non-users.
Complementing epidemiological findings, translational neuroimaging research led by Risacher et al. (2016) explored in vivo structural and metabolic markers associated with anticholinergic burden. Utilizing magnetic resonance imaging (MRI) and fluorodeoxyglucose positron emission tomography (FDG-PET), the investigators discovered that cognitively intact older adults taking medications with medium-to-high anticholinergic activity exhibited accelerated total brain atrophy, localized volume loss within the hippocampus and temporal lobes, and reduced glucose metabolism across the cortex. These structural perturbations directly correlated with lower scores on immediate memory assessments and executive function panels, indicating that anticholinergic exposure confers true biological neurotoxicity rather than just temporary functional sedation.
Furthermore, research evaluating the reversibility of anticholinergic-induced cognitive deficits demonstrates that while acute symptoms typically resolve following drug discontinuation, chronic exposure may deplete cognitive reserve and accelerate the onset of permanent neurodegenerative cascades, particularly in individuals with pre-existing amyloid-beta or tau pathology.
12. Cultural & Cross-Cultural Considerations
The incidence, clinical manifestation, and clinical management of anticholinergic effects vary globally across diverse healthcare systems, regulatory landscapes, and cultural health traditions. A primary source of international variance lies in the accessibility and over-the-counter availability of potent anticholinergic medications.
In North America and certain Western European nations, first-generation H1-antihistamines (such as diphenhydramine and chlorpheniramine) and belladonna-derived gastrointestinal formulations are readily obtainable without a medical prescription. Consumers frequently self-administer these compounds as sleep aids, allergy medications, and motion sickness remedies without clinical oversight, dramatically increasing the prevalence of unmonitored anticholinergic burden in older populations. In contrast, several European and East Asian nations enforce stricter regulatory control over first-generation sedating antihistamines and antispasmodics, mitigating community-level exposure.
Cross-cultural patterns of polypharmacy also influence vulnerability. In rapidly aging nations with fragmented specialized healthcare delivery models, elderly patients frequently receive concurrent care from distinct physicians who prescribe multiple drugs with unrecognized additive anticholinergic affinities. In addition, traditional medicine practices globally incorporate botanical preparations containing natural tropane alkaloids—such as Datura in traditional Ayurvedic, African, and Latin American folk healing traditions—which can trigger acute anticholinergic toxidromes that present to clinical facilities unfamiliar with traditional pharmacognosy.
13. Criticisms, Debates & Limitations
Despite robust literature warning against excessive anticholinergic use, significant debate persists within academic medicine regarding the methodologies used to estimate anticholinergic burden and the exact causality of long-term outcomes.
A central criticism targets the methodology of Anticholinergic Burden Scales. Existing scoring instruments (e.g., ACB, ARS, DBI) exhibit marked heterogeneity: a specific medication categorized as a high-potency agent (score of 3) on one scale may be ranked as moderate (score of 2) or even omitted from another. Furthermore, many of these scales assign static scores based on expert consensus rather than active concentration-response bioassays, failing to account for individual variations in drug dose, renal clearance, hepatic cytochrome P450 metabolism, and blood-brain barrier permeability.
Another ongoing debate centers on protopathic bias and reverse confounding within observational epidemiological studies. Critics point out that early prodromal symptoms of neurodegenerative disease—such as sleep disturbances, mild depressive symptoms, urinary urgency, and functional somatic complaints—frequently prompt healthcare providers to prescribe agents possessing anticholinergic actions (e.g., sedating antidepressants, bladder stabilizers). Consequently, it remains challenging to definitively prove whether chronic anticholinergic exposure causes dementia or if patients in the prodromal phases of dementia are systematically prescribed more anticholinergic medications prior to formal diagnosis.
Finally, clinical debates continue concerning the risk-benefit trade-offs of anticholinergic prescribing in targeted conditions. While deprescribing initiatives advocate for the complete elimination of high-risk compounds, geriatricians and psychiatrists caution that abrupt cessation can precipitate severe rebound phenomena, including withdrawal cholinergic crises, profound insomnia, acute dystonic recurrences, or severe urinary urge incontinence that independently harms a patient’s functional autonomy and quality of life.
14. Related Terms & Distinctions
To ensure diagnostic clarity, anticholinergic effects must be differentiated from closely allied pharmacological concepts and toxidromes:
- Anticholinergic vs. Sympathomimetic Toxicity: Both toxidromes manifest with severe agitation, pupillary dilation (mydriasis), and marked sinus tachycardia. However, the definitive physical distinction resides in cutaneous secretory activity: the anticholinergic patient presents with parched, hot, anhidrotic skin and absent bowel sounds, whereas the sympathomimetic patient (e.g., cocaine or amphetamine toxicity) presents with profuse diaphoresis and active peristalsis.
- Anticholinergic Burden vs. Sedative Burden: Anticholinergic burden measures the cumulative physiological and central antagonism of acetylcholine, whereas sedative burden measures central nervous system depression mediated primarily via gamma-aminobutyric acid (GABA) receptor modulation. While some medications possess both properties, their mechanisms, cognitive profiles, and peripheral manifestations remain distinct.
- Antimuscarinic vs. Antinicotinic Effects: Antimuscarinic effects are mediated specifically by the inhibition of G-protein coupled muscarinic receptors (M1–M5), encompassing the classical autonomic and cognitive phenomena observed in clinical medicine. Antinicotinic effects refer to the interruption of ligand-gated ion channels at the neuromuscular junction (yielding muscular flaccidity or paralysis) or autonomic ganglia (causing autonomic ganglionic blockade).
- Cholinergic Crisis (The Inverse Phenomenon): Characterized by an overabundance of acetylcholine stimulation at the synaptic cleft (provoked by organophosphate insecticides or acetylcholinesterase inhibitors). The resulting clinical state is the antithesis of anticholinergic effects, characterized by the SLUDGE mnemonic: Salivation, Lacrimation, Urination, Defecation, Gastrointestinal distress, and Emesis, accompanied by miosis and bradycardia.
15. Summary / Key Takeaways
Anticholinergic effects represent the broad clinical manifestations of muscarinic and nicotinic receptor blockade across peripheral and central nervous systems. While deliberately harnessed in selected settings—such as anesthesia, pulmonary bronchodilation, and the stabilization of overactive detrusor tissue—unintentional anticholinergic actions present significant clinical challenges across medicine and psychiatry.
Central nervous system manifestations range from mild executive processing delays and memory consolidation deficits to delirium and visual hallucinations. Peripherally, smooth muscle relaxation and glandular suppression produce the classic triad of dry mouth, blurred vision, and urinary retention, alongside sinus tachycardia and constipation. The accumulation of these medications leads to significant anticholinergic burden, which has been consistently associated in longitudinal research with an elevated risk of cognitive decline, functional dependence, and long-term dementia.
Optimizing clinical outcomes requires heightened diagnostic vigilance, the utilization of validated burden indices, an appreciation for the differential diagnosis between anticholinergic and sympathomimetic toxicity, and a commitment to judicious deprescribing protocols aimed at minimizing unnecessary polypharmacy in vulnerable populations.
References
- Boustani, M., Campbell, N., Munger, S., Maidment, I., & Fox, C. (2008). Impact of anticholinergics on the aging brain: A review and practical application. Aging Health, 4(3), 311–320. https://doi.org/10.2217/1745509X.4.3.311
- Coupland, C. A. C., Hill, T., Dening, T., Morriss, R., Moore, M., & Hippisley-Cox, J. (2019). Anticholinergic drug exposure and the risk of dementia: A nested case-control study. JAMA Internal Medicine, 179(8), 1084–1093. https://doi.org/10.1001/jamainternmed.2019.0677
- Dale, H. H. (1914). The action of certain esters and ethers of choline, and their relation to muscarine. Journal of Pharmacology and Experimental Therapeutics, 6(2), 147–190.
- Risacher, S. L., McDonald, B. C., Tallman, E. F., West, J. D., Farlow, M. R., Unverzagt, F. W., Gao, S., Boustani, M., Crane, P. K., Petersen, R. C., Jack, C. R., Jagust, W. J., Aisen, P. S., Weiner, M. W., & Saykin, A. J. (2016). Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurology, 73(6), 721–732. https://doi.org/10.1001/jamaneurol.2016.0580
- Rudolph, J. L., Salow, M. J., Angelini, M. C., & McGlinchey, R. E. (2008). The Anticholinergic Risk Scale and anticholinergic adverse effects in older persons. Archives of Internal Medicine, 168(5), 508–513. https://doi.org/10.1001/archinternmed.2007.106